First Time Loading...
I

Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 69.44 USD -1.28% Market Closed
Updated: May 4, 2024

Intra-Cellular Therapies Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Cash from Operating Activities Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
I
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Cash from Operating Activities
-$124.2m
CAGR 3-Years
19%
CAGR 5-Years
-1%
CAGR 10-Years
-19%
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$22.8B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$13.7B
CAGR 3-Years
-1%
CAGR 5-Years
17%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$8.7B
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$13B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$4.2B
CAGR 3-Years
-13%
CAGR 5-Years
-5%
CAGR 10-Years
-3%

See Also

What is Intra-Cellular Therapies Inc's Cash from Operating Activities?
Cash from Operating Activities
-124.2m USD

Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Cash from Operating Activities amounts to -124.2m USD.

What is Intra-Cellular Therapies Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-19%

Over the last year, the Cash from Operating Activities growth was 54%. The average annual Cash from Operating Activities growth rates for Intra-Cellular Therapies Inc have been 19% over the past three years , -1% over the past five years , and -19% over the past ten years .